$ALNY ALNYLAM PHARMACEUTICALS, INC. Insider Trading
Get free email notifications about insider trading in ALNYLAM PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ALNYLAM PHARMACEUTICALS, INC.. Insider overview, share value development, latest insider transactions and email notifications about new events in ALNYLAM PHARMACEUTICALS, INC. for free.
IRS Number: 770602661
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Trading Symbol: ALNY
Company Address: 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE 02142
Former name: ALNYLAM PHARMACEUTICALS INC, date of change: 2002-07-24
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Market Capitalization: $3.49B
Prev close: $40.46
Average Daily Volume: 1,254,630
Days Low: $39.66
Year Low: $31.38
Year High: $80.11
ALNYLAM PHARMACEUTICALS, INC. Latest Insider Transactions
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Option Exercise | M | 7.10 | 33,979 | 241,251 | 67,957 | |
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Sell | S | 134.37 | 1,023 | 137,461 | 214,765 | 215.8 K to 214.8 K (-0.47 %) |
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Sell | S | 133.56 | 1,624 | 216,901 | 215,788 | 217.4 K to 215.8 K (-0.75 %) |
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Sell | S | 132.32 | 3,481 | 460,606 | 217,412 | 220.9 K to 217.4 K (-1.58 %) |
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Sell | S | 131.18 | 11,203 | 1,469,610 | 220,893 | 232.1 K to 220.9 K (-4.83 %) |
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Sell | S | 130.34 | 9,121 | 1,188,831 | 232,096 | 241.2 K to 232.1 K (-3.78 %) |
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Sell | S | 129.32 | 4,512 | 583,492 | 241,217 | 245.7 K to 241.2 K (-1.84 %) |
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Sell | S | 128.30 | 3,015 | 386,825 | 245,729 | 248.7 K to 245.7 K (-1.21 %) |
May 17 2021 | ALNY | ALNYLAM PHARMACEUT ... | MARAGANORE JOHN | Chief Executive Off ... | Buy | M | 7.10 | 33,979 | 241,251 | 248,744 | 214.8 K to 248.7 K (+15.82 %) |
Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 138.48 | 107 | 14,817 | 14,119 | 14.2 K to 14.1 K (-0.75 %) |
Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 137.60 | 530 | 72,928 | 14,226 | 14.8 K to 14.2 K (-3.59 %) |
Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 136.84 | 1,892 | 258,901 | 14,756 | 16.6 K to 14.8 K (-11.36 %) |
Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Sell | S | 135.41 | 203 | 27,488 | 16,648 | 16.9 K to 16.6 K (-1.20 %) |
Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Payment of Exercise | F | 134.56 | 85 | 11,438 | 16,851 | 16.9 K to 16.9 K (-0.50 %) |
Apr 21 2021 | ALNY | ALNYLAM PHARMACEUT ... | Vaishnaw Akshay | President, R&D | Payment of Exercise | F | 131.75 | 2,266 | 298,546 | 16,936 | 19.2 K to 16.9 K (-11.80 %) |
View all ALNYLAM PHARMACEUTICALS, INC. insider transactions.